Real-World Tocilizumab Use in Pediatric Inpatients.

Tocilizumab indications included cytokine release syndrome (CRS; 56%), autoimmune disease (27%), graft-versus-host disease (GVHD; 5%), and COVID-19 (4%).

Of 29 courses with evaluable hematologic data, 10% resulted in new-onset neutropenia and 3% in severe thrombocytopenia.

Overall survival to discharge was 83%.

In multivariable analyses, independent associations with mortality were found for the use of extracorporeal support (OR, 8.68; 95% CI, 1.85-4.87), oncologic diagnosis (OR, 7.07; 95% CI, 1.14-89.29), and post-tocilizumab infection (OR, 11.17; 95% CI, 1.50-138.13).